On-demand recording and key takeaway available: Insilico introduces generative AI platform enhancements across drug discovery stages in Pharma.ai summer updates webinar

Below are some highlights from the Summer Pharma.ai platform updates:


Generative Biologics, the AI-empowered platform for biologics generation and optimization

• Candidate production with higher contact numbers and lower ΔG (binding free energy):

This new generative model takes a diffusion-based approach for generating antibody scaffolds and sequences, allowing conditioning on specific frameworks for customized designs.

• Retrieve and visualize protein structures directly from the RCSB database:

Type the protein PDB code of interest, and the Generative Biologics platform will automatically upload the PDB ID and title, including the experiment method and resolution, and pre-process the file..

• Updated results page with more details and better visualization:

The results page now displays detailed non-covalent interactions (e.g., hydrogen bonds, stacking interactions), includes filtering and sorting options, and visualizes selected interaction types using dashed lines.

• More powerful peptide library screening function based on built-in templates:

Screen peptide libraries against an existing template, with point mutation analyses and comparison with original templates enabled.



Chemistry42, the generative chemistry platform combining AI flexibility and physics-based precision

• Alchemistry 2.0 - A physics-based module with an increase of up to fourfold in the speed and improved accuracy:

Version 2.0 has an enhanced architecture for scalability and efficient GPU resource usage, demonstrating strong performance across various target types (enzymes, GPCRs, etc).

• Updated interface with more information:

Visualization and the ability to download the molecular dynamics are now available in version 2.0.



PandaOmics, a cloud-based omics analysis platform generating biological insights with AI

• New functions to streamline research and development:

Duplicate and customize curated meta-analyses, and upload multi-entry data for detailed sample analysis。

• Safer environments and easier sharing:

Virtual Private Cloud (VPC) and Single Sign-On (SSO) for enhanced data security and scalability, and knowledge graph export for usage in reports or manuscripts.



DORA, your advanced AI-driven research assistant, is transforming biomedical document production

• Open-source release with paid versions tailored for specific user groups:

Planned community open-source release along with SaaS and enterprise editions offering various access and deployment options.



PreciousGPT, multimodal transformers for omics data and living system simulation

• Free access enabled for multiple aging clock through open Python library:

Researchers can now access dozens of aging clocks mentioned in publications from Harvard, Oxford, the University of Connecticut and Insilico Medicine, along with ipf-P3GPT for studying the aging process in fibrotic diseases.



In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico has been integrating technical breakthroughs into the Pharma.AI suite, a generative AI-powered solution spanning biology, chemistry, medicine development, and science research. Since its inception in 2014, Insilico has published over 200 peer-reviewed papers and has held more than 600 patents and patent applications.